Graphic featuring a syringe to illustrate an HIV vaccine trial

Innovation-opedia: What is a mosaic vaccine?

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Written by Johnson & Johnson

| July 22, 2019

July 22, 2019

Illustrated handwritten definition of a mosaic HIV vaccine

Illustration of a microscope with information about Janssen Vaccines & Prevention B.V. investigational HIV-1 vaccine regimen

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_above

Illustration of the # 4 explaining how many injections would be administered for Janssen’s investigational HIV-1 vaccine.

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_below

Illustration showing location of the IAS Conference on HIV Science with details about Janssen’s new Mosaico clinical trial.

Illustrated quote by Janssen’s Maria Grazia Pau talking about the goal of creating a global HIV vaccine.

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

CTA-Red ribbon HIV

HIV vaccine J&J Innovative Medicine Johnson & Johnson

More from Johnson & Johnson

Health & wellness

September 18, 2026

Patients share what it’s like to have wAIHA, a disease that causes the immune system to destroy red blood cells

Warm autoimmune hemolytic anemia is a rare, life-threatening disease that causes intense fatigue. Johnson & Johnson has a new therapy that targets the underlying drivers of the disease. Here, two patients—and Johnson & Johnson employees—share their journey, from symptoms and diagnosis to managing work and personal life.

Read more
Health & wellness

September 17, 2026

5 things we now know about prostate cancer

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.

Read more
Innovation

September 14, 2026

Striving for a cure for multiple myeloma: What HCPs need to know

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Read more